Example: Heart Attack

Clinical Trials on Systemic Onset Juvenile Idiopathic Arthritis

Total 46 results

NCT00339157

Completed

Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS

Conditions: Systemic-Onset Juvenile Idiopathic Arthritis
NCT00868751

Terminated

Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis

Conditions: Arthritis, Juvenile Rheumatoid; Still's Disease, Juvenile Onset
NCT00570661

Completed

Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)

Conditions: Active Systemic; Onset Juvenile Idiopathic Arthritis
NCT04752371

Not yet recruiting

A Study to Evaluate AEVI-007 in Participants With Adult Onset Still's Disease

Conditions: Adult Onset Still's Disease
NCT03651193

Recruiting

Multi-center Registration Study of Adult Onset Still's Disease in Chinese Population

Conditions: Adult Onset Still Disease
NCT04750863

Completed

Evaluation of Adult Onset Still Disease Classification Criteria and Differential Diagnosis at Eighteen Months of Follow-up

Conditions: Adult Onset Still Disease
NCT02204293

Terminated

Canakinumab for Treatment of Adult-onset Still's Disease

Conditions: Adult-Onset Still´s Disease
NCT03265132

Terminated

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

Conditions: Still's Disease, Adult-Onset; Still's Disease, Juvenile-Onset
NCT02398435

Completed

Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease

Conditions: Still's Disease, Adult-Onset
NCT01002781

Unknown status

Efficacy and Safety of Tocilizumab in Adult's Still Disease

Conditions: Adult's Still Disease
NCT01033656

Completed

Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study

Conditions: Adult-Onset Still's Disease
NCT01676948

Withdrawn

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Conditions: Systemic Juvenile Idiopathic Arthritis
NCT03932344

Completed

Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Conditions: Still Disease, Juvenile Onset
NCT03276650

Completed

Admission of Adult-onset Still Disease Patients in the ICU

Conditions: Adult-Onset Still Disease; Critically Ill
NCT00891046

Completed

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

Conditions: Systemic Juvenile Idiopathic Arthritis
NCT01803321

Completed

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Conditions: Systemic Juvenile Idiopathic Arthritis
NCT04717635

Not yet recruiting

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Conditions: Adult Onset Still's Disease
NCT00889863

Completed

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Conditions: Systemic Juvenile Idiopathic Arthritis With Active Flare
NCT02334748

Completed

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Conditions: Systemic Juvenile Idiopathic Arthritis; Hereditary Periodic Fevers
NCT03510442

Recruiting

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions

Conditions: Still's Disease, Adult-Onset; Systemic Inflammation; Arthritis; Autoinflammatory Syndrome
NCT00886769

Terminated

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Conditions: Systemic Juvenile Idiopathic Arthritis
NCT04088396

Recruiting

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA

Conditions: Systemic Juvenile Idiopathic Arthritis
NCT00144599

Completed

Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Conditions: Systemic Juvenile Idiopathic Arthritis
NCT00144612

Completed

Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Conditions: Systemic Juvenile Idiopathic Arthritis
NCT02396212

Completed

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Conditions: Systemic Juvenile Idiopathic Arthritis